ImmuPharma PLC (UK) Buy Hold or Sell Recommendation
| IMM Stock | 1.47 0.08 5.16% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding ImmuPharma PLC is 'Strong Sell'. Macroaxis provides ImmuPharma PLC buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IMM positions.
Check out ImmuPharma PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as ImmuPharma and provide practical buy, sell, or hold advice based on investors' constraints. ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
ImmuPharma |
Execute ImmuPharma PLC Buy or Sell Advice
The ImmuPharma recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ImmuPharma PLC. Macroaxis does not own or have any residual interests in ImmuPharma PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ImmuPharma PLC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
ImmuPharma PLC Trading Alerts and Improvement Suggestions
| ImmuPharma PLC may become a speculative penny stock | |
| ImmuPharma PLC has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.92 M) with profit before overhead, payroll, taxes, and interest of 118.35 K. | |
| ImmuPharma PLC generates negative cash flow from operations | |
| About 48.0% of the company shares are held by company insiders |
ImmuPharma PLC current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ImmuPharma analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ImmuPharma analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
ImmuPharma PLC Returns Distribution Density
The distribution of ImmuPharma PLC's historical returns is an attempt to chart the uncertainty of ImmuPharma PLC's future price movements. The chart of the probability distribution of ImmuPharma PLC daily returns describes the distribution of returns around its average expected value. We use ImmuPharma PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ImmuPharma PLC returns is essential to provide solid investment advice for ImmuPharma PLC.
| Mean Return | 0.05 | Value At Risk | -5.16 | Potential Upside | 4.05 | Standard Deviation | 3.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ImmuPharma PLC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ImmuPharma PLC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ImmuPharma PLC or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ImmuPharma PLC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ImmuPharma stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.05 | |
σ | Overall volatility | 2.97 | |
Ir | Information ratio | -0.03 |
ImmuPharma PLC Volatility Alert
ImmuPharma PLC shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ImmuPharma PLC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ImmuPharma PLC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ImmuPharma PLC Fundamentals Vs Peers
Comparing ImmuPharma PLC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ImmuPharma PLC's direct or indirect competition across all of the common fundamentals between ImmuPharma PLC and the related equities. This way, we can detect undervalued stocks with similar characteristics as ImmuPharma PLC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ImmuPharma PLC's fundamental indicators could also be used in its relative valuation, which is a method of valuing ImmuPharma PLC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ImmuPharma PLC to competition |
| Fundamentals | ImmuPharma PLC | Peer Average |
| Return On Equity | -1.11 | -0.31 |
| Return On Asset | -0.43 | -0.14 |
| Operating Margin | 36.15 % | (5.51) % |
| Current Valuation | 6.02 M | 16.62 B |
| Shares Outstanding | 416.44 M | 571.82 M |
| Shares Owned By Insiders | 48.33 % | 10.09 % |
| Shares Owned By Institutions | 17.44 % | 39.21 % |
| Price To Book | 2.31 X | 9.51 X |
| Price To Sales | 60.75 X | 11.42 X |
| Gross Profit | 118.35 K | 27.38 B |
| EBITDA | (3.03 M) | 3.9 B |
| Net Income | (2.92 M) | 570.98 M |
| Total Debt | 1.67 M | 5.32 B |
| Book Value Per Share | 0.01 X | 1.93 K |
| Cash Flow From Operations | (1.36 M) | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 5 | 18.84 K |
| Beta | 1.58 | -0.15 |
| Market Capitalization | 6.76 M | 19.03 B |
| Total Asset | 2.72 M | 29.47 B |
| Retained Earnings | (64.08 M) | 9.33 B |
| Working Capital | (321.92 K) | 1.48 B |
| Net Asset | 2.72 M |
ImmuPharma PLC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ImmuPharma . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ImmuPharma PLC Buy or Sell Advice
When is the right time to buy or sell ImmuPharma PLC? Buying financial instruments such as ImmuPharma Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ImmuPharma PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Petroleum and Natural Gas Thematic Idea Now
Petroleum and Natural Gas
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Petroleum and Natural Gas theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Petroleum and Natural Gas Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.